883908-09-6

Basic information

• Product Name: 2-oxo-2H-chromene-3-carboxylic acid [2-(4-benzyl-piperazin-1-yl)-5-bromo-phenyl]-amide
• Synonyms: 2-oxo-2H-chromene-3-carboxylic acid [2-(4-benzyl-piperazin-1-yl)-5-bromo-phenyl]-amide
• CAS NO: 883908-09-6
• Molecular Weight: 518.41
• Mol File: 883908-09-6.mol

Chemical Properties

• CAS DataBase Reference: 2-oxo-2H-chromene-3-carboxylic acid [2-(4-benzyl-piperazin-1-yl)-5-bromo-phenyl]-amide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-oxo-2H-chromene-3-carboxylic acid [2-(4-benzyl-piperazin-1-yl)-5-bromo-phenyl]-amide(883908-09-6)
• EPA Substance Registry System: 2-oxo-2H-chromene-3-carboxylic acid [2-(4-benzyl-piperazin-1-yl)-5-bromo-phenyl]-amide(883908-09-6)

Safety Data

• Hazardous Substances Data: 883908-09-6(Hazardous Substances Data)

Upstream product

• 89-95-2 2-methyl-benzyl alcohol 
• 2759-28-6 1-phenylmethylpiperazine 
• 883908-27-8 1-benzyl-4-(2-amino-4-bromo-phenyl)-piperazine 
• 531-81-7 2-oxo-2H-chromene-3-carboxylic acid 
• 883522-59-6 1-benzyl-4-(4-bromo-2-nitro-phenyl)-piperazine 

Relevant articles and documents

BACE-1 inhibitory activities of new substituted phenyl-piperazine coupled to various heterocycles: Chromene, coumarin and quinoline

The protease β-secretase plays a central role in the synthesis of pathogenic amyloid-β in Alzheimer's disease. Here, we report a new series of analogues based on the phenyl-piperazine scaffold coupled to various heterocyclic moieties, which demonstrate improved inhibitory activities on BACE-1 (FRET assay) compared to already known naphthyl counterparts. The obtained results suggest further structural modifications to access to more potent BACE-1 inhibitors.

Naphthyl and coumarinyl biarylpiperazine derivatives as highly potent human β-secretase inhibitors. Design, synthesis, and enzymatic BACE-1 and cell assays

Twenty novel β-secretase inhibitors containing biarylpiperazine moieties belonging to naphthyl and coumarinyl series were designed for their potential use in Alzheimer's disease therapy. Enzymatic and cell-based assays have been carried out. The biological results clearly demonstrate that specific substituents located at the N4-position of the piperazine ring result in excellent in vitro inhibitory potency (IC50 values ranging between 40 and 70 nM), Variable temperature NMR and modeling studies are consistent with the obtained biological data, since these studies confirmed that introduction at the N4-position of the piperazine ring allows productive interactions within the BACE-1 active site, which appear to be determinative for high BACE-1 inhibitory activity. These results are of particular interest since some of the new analogues belonging to the naphthyl series are almost one log more active than the best inhibitor of the similar family recently reported.